CGRP inhibitors linked to 25% lower glaucoma risk in migraine patients

Migraine patients may experience improved health outcomes and reduced blindness risk, potentially justifying higher out-of-pocket costs for CGRP inhibitors over cheaper alternative migraine treatments. Patients with both migraine and glaucoma risk factors gain additional therapeutic benefit.

Regulatory bodies may expand CGRP inhibitor indications to include glaucoma prevention, potentially broadening insurance coverage. Health systems may shift formulary preferences toward CGRP inhibitors, increasing reimbursement pressure. Further clinical trials may be mandated to establish causation and optimal dosing for dual benefits.

Medical optimism framing with cautious language. The headline emphasizes the positive finding ('linked to 25% lower risk') while the body text repeatedly clarifies this is associational, not causal. The article frames CGRP inhibitors favorably by explaining the biological plausibility of the mechanism.